Filing Flows › Kura Oncology (KURA) › R&D spending
Kura Oncology (KURA) R&D spending by quarter
Kura Oncology's R&D spending was $61.9M in Q2 2026 (second quarter 2026), -5% from Q1 2026. Over the last 6 quarters it ranged from $56.0M (Q1 2025) to $67.9M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $61.9M | -5% | -1% |
| Q1 2026 | $65.3M | +1% | +17% |
| Q4 2025 | $64.4M | -5% | — |
| Q3 2025 | $67.9M | +8% | — |
| Q2 2025 | $62.8M | +12% | — |
| Q1 2025 | $56.0M | — | — |
Q2 2026 at a glance
Kura Oncology, Q2 2026: revenue $20.9M (+36% year over year), operating margin -349.8%, net loss $68.3M, operating cash flow −$62.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Kura Oncology's R&D spending?
Kura Oncology's R&D spending was $61.9M in Q2 2026 (second quarter 2026), -5% from Q1 2026.
How has Kura Oncology's R&D spending changed?
Over the last 6 quarters it ranged from $56.0M (Q1 2025) to $67.9M (Q3 2025).